COVID-19: Europe and Canada reviewing Johnson & Johnson’s vaccine
COVID-19: Europe and Canada reviewing Johnson & Johnson’s vaccine. European and Canadian regulatory authorities conduct reviewing of Johnson & Johnson’s COVID-19 vaccine
Reuters news on December 1, European health regulators said on Tuesday that they have begun a real-time review of the new coronavirus vaccine candidate developed by Johnson & Johnson, because preliminary results show that the vaccine promotes the human body to produce new coronavirus antibodies and immune cells.
The European Medicines Agency (EMA) stated that the review will continue until there is sufficient evidence to support the official marketing authorization application for the vaccine. The vaccine was developed by Janssen, a subsidiary of Johnson & Johnson.
At the same time, Canadian Health Minister Patty Hajdu said on Twitter that Johnson & Johnson has submitted its candidate vaccine to Health Canada for review. This is the fourth vaccine to open the approval process in Canada. Vaccine candidates developed by Pfizer, BioNTech, Moderna, and AstraZeneca are currently under review by Health Canada.
Johnson & Johnson did not immediately respond to Reuters’ request for comment on Hajdu’s tweet.
Moderna has applied for European COVID-19 vaccine authorization
According to Bloomberg’s news on December 1, Moderna has applied for European COVID-19 vaccine authorization.
It is reported that Moderna previously stated in a statement that the effective rate of the COVID-19 vaccine developed by it is 94.1%, and the effective rate for severely ill patients can even reach 100%.